08:20 AM EDT, 10/13/2025 (MT Newswires) -- Tvardi Therapeutics ( TVRD ) said Monday that a phase 2 clinical trial of its drug TTI-101 as a potential treatment for idiopathic pulmonary fibrosis failed to meet its goals.

Preliminary data from the 88-patient study showed that patients who received 400 milligrams, 800 milligrams, or a placebo showed "no statistically significant differences," the company said.

The company also reported $41.0 million in cash, cash equivalents, and short-term investments, as of June 30, expected to fund operations into Q4 of 2026.

Idiopathic pulmonary fibrosis is a rare, progressive illness of the respiratory system that leads to irreversible declines in lung function.

Shares of the company fell more than 80% in recent premarket activity.